Welcome to Drawbridge Pharmaceuticals


Drawbridge Pharmaceuticals P/L is a public  company limited by shares, developing neuroactive steroid compounds for use in critical care situations.  The properties of these compounds include anaesthesia and sedation, anticonvulsant activity and neuroprotection. Phaxan™, the lead compound, is a fast onset and offset intravenous general anaesthetic and sedative that protects the brain from the harmful effects of insults such as hypoxia and trauma.  The potent anticonvulsant and neuroprotective effects of Phaxan™ occur at doses that cause none or minimal cardiovascular depression.  As such, Phaxan™ offers significant clinical and safety advances over currently available sedatives and hypnotics.

Phaxan® has the highest therapeutic safety margin ever described for any anaesthetic drug.

FDA rules warnings to be added to the labels of all commonly used anaesthetics:  safety concerns for late pregnancy babies and children less than 3 years old.

“Drawbridge will address this issue as a priority in the development and commercialisation of Phaxan®

Figure 1: Comparison of anaesthetics in animal models of anaesthesia in early life: data from published literature on programmed cell death (apoptosis) in the brains of foetal and neonatal animals. 

front-page-graphCLICK HERE TO READ MORE